- PROVIDERS
- LIFE SCIENCES
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
- ABOUT US
Content
-
ArticlesQ&A: De-Risking Clinical Trials with Real-World Data
Iker Huerga, SVP, Life Sciences Strategy and RWD at Tempus, discusses how heterogeneous data sources can strengthen clinical trial planning and execution to de-risk research. -
ArticlesAdvancing immuno-oncology with real-world data
Discover how TScan uses RWD to power companion diagnostic and drug development and ensure the right patients are involved in their clinical studies. -
Case StudiesAccelerate Trial Enrollment with TIME
Learn how TIME gave Sermonix access to a network of providers and patients to accelerate enrollment in ELAINE II. -
WebinarsMultimodal data drives biomarker innovation
We spoke with Gilead experts to learn how the company uses multimodal data to achieve early successes in translational biomarker research and discovery. -
ArticlesDual testing in metastatic breast cancer
Tempus research exploring the concordance of pathogenic variants across a variety of criteria for metastatic breast cancer patients. -
ArticlesData-driven companion diagnostic development
At the World Clinical Biomarkers and CDx Summit, biopharma leaders shared how they’re using RWD in oncology to drive CDx and therapeutic innovation. -
ArticlesNew research seeks to explain difference in ICB therapy response
Tempus developed an integrative model of tumor-extrinsic and tumor-intrinsic features associated with longer time to progression in NSCLC patients. -
ArticlesHow to Use RWD for Good with Najat Khan, Ph.D
Check out how Janssen’s R&D Data Science team is using RWD and AI to bring more targeted treatments to patients, saving lives. -
ArticlesTop 8 takeaways from the ESMO Congress 2022
Check out the latest on personalized medicine’s continued progress with this overview of new evidence from key trials, by Tempus’ Dr. Calvin Chao. -
ArticlesPatient recruitment at the speed of science
Learn how Sermonix Pharmaceuticals partnered with Tempus and its TIME network of clinical sites to accelerate patient recruitment for a phase 2 study. -
ArticlesThe promise of multimodal real-world data
In this Q&A with Dr. Hisham Hamadeh of Genmab, we explore how using multimodal RWD can help organizations solve their toughest drug development challenges. -
ArticlesNavigating biomarker validation
Attaining biomarker validation is not a one-size-fits-all process. Find out how to optimize a biomarker to increase its chance of widespread adoption. -
ArticlesGetting to the heart of multimodal data
Go behind the scenes with Tempus COO Ryan Fukushima and learn how harmonized multimodal data sources help accelerate and de-risk drug development programs. -
Case StudiesSequencing for development and commercialization
If you’re wondering how Tempus’s sequencing services can help your project move forward, consider the experiences of these four organizations, who partnered with Tempus for prospective sequencing for clinical trials, retrospective sequencing and analyses, companion diagnostic development, and sponsored testing. -
Case StudiesPowering Discovery: Tempus Multimodal Database
Targeting discovery is an important frontier in the fight against pancreatic cancer. Take a look at this example of how the Tempus Multimodal Database enabled a pharmaceutical company to more quickly identify pancreatic cancer subtypes’ molecular signatures. -
Case StudiesHow to identify unmet medical need with Tempus RWD
See how Tempus RWD enabled a biopharma company to correlate biomarker expression levels to patient outcomes on SoC therapies. -
Case StudiesEnhanced biomarker discovery and design
Combining sequencing, analytics, and data licensing with Tempus allows you to uncover new insights across the research and development spectrum. This case study shows how one company made it happen. -
WebinarsThe next evolution in drug development
We spoke with Janssen’s Dr. Najat Khan to find out how the company is applying advanced AI algorithms to RWD – with groundbreaking results.
